2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Обновление рекомендаций Американской коллегии ревматологов 2008 года по применению базисных противоревматических препаратов и биологических средств для лечения ревматоидного артрита, 2012 год
Jasvinder A. Singh, Daniel E. Fürst, Aseem Bharat, Jeffrey R. Curtis, Arthur F. Kavanaugh, Joel M. Kremer, Larry W. Moreland, James R. O’Dell, Kevin Winthrop, Timothy Beukelman, S. Louis Bridges, W. Winn Chatham, Harold E. Paulus, María E. Suarez‐Almazor, Claire Bombardier, Maxime Dougados, Dinesh Khanna, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Eileen Moynihan, Karen S. Kolba, Archana Jain, Elizabeth R. Volkmann, Harsh Agrawal, Sangmee Bae, Amy S. Mudano, Nivedita M. Patkar, Kenneth G. Saag
2012-04-02

American College of Rheumatologybiologic agentsdisease-modifying antirheumatic drugsrheumatoid arthritistreatment recommendations
Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their application to be made by the physician in light of each patient's individual circumstances.Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome.Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revision as warranted by the evolution of medical knowledge, technology, and practice.
1
Application of the recommendations is voluntary and should be determined by physicians according to each patient’s circumstances.
2
The 2012 ACR update revises the 2008 recommendations for using disease-modifying antirheumatic drugs and biologic agents to treat rheumatoid arthritis.
3
The guidelines are subject to periodic revision as medical knowledge, technology, and clinical practice evolve.
4
The recommendations aim to promote beneficial outcomes but cannot guarantee any specific clinical outcome.
5
The recommendations provide guidance for particular treatment patterns but are not intended to dictate care for individual patients.

Disease-modifying antirheumatic drugs and biologic agents used in the treatment of rheumatoid arthritis

Recommendations and guidance for the use of these therapies in rheumatoid arthritis treatment

Publication Details
Publication Date
2012-04-02
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Jasvinder A. Singh
Daniel E. Fürst
Aseem Bharat
Jeffrey R. Curtis
Arthur F. Kavanaugh
Joel M. Kremer
Larry W. Moreland
James R. O’Dell
Kevin Winthrop
Timothy Beukelman
S. Louis Bridges
W. Winn Chatham
Harold E. Paulus
María E. Suarez‐Almazor
Claire Bombardier
Maxime Dougados
Dinesh Khanna
Charles M. King
Amye Leong
Eric L. Matteson
John T. Schousboe
Eileen Moynihan
Karen S. Kolba
Archana Jain
Elizabeth R. Volkmann
Harsh Agrawal
Sangmee Bae
Amy S. Mudano
Nivedita M. Patkar
Kenneth G. Saag
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%